Targeting Genetic
Drivers of Neurodegeneration

Pipeline

VO659

VO659 is an innovative antisense oligonucleotide (ASO) therapy that targets the genetic drivers of polyglutamine diseases. These neurological conditions, including Huntington’s disease and various spinocerebellar ataxias, are caused by a mutation leading to abnormally long polyglutamine sequences in key proteins. This makes the mutant proteins toxic to nerve cells, causing neurodegeneration.

Directly Targeting the CAG Repeat Expansion Mutation:

By focusing on the specific mutation, our therapy has the potential to address the root cause of these diseases.

Allele Preferentiality:

Importantly, our ASOs are designed to primarily target the mutated gene, limiting the impact on healthy cells and reducing potential side effects.

Vo659 mechanism of action diagram
Scroll to Top
Leadership
Leadership micah mackison

Leadership

Micah Mackison

Chief Executive Officer
Linkedin icon

Mr. Micah Mackison was appointed CEO of Vico Therapeutics in August 2022. Prior to this role, Micah served as Chief Business Officer and Executive Vice President of Strategy and Corporate Development at Locanabio, an RNA-targeted gene therapy company. At Locanabio, he was instrumental in setting strategy, raising capital and helping build an organization focused on genetic neurological diseases. Prior to Locanabio, Micah held several leadership positions in corporate development and strategy. He served as Senior Vice President, Corporate Development and Strategy at Assembly Biosciences where he led business development efforts. Previously, Micah served as Head of Corporate Strategy and Senior Director, New Ventures at H. Lundbeck A/S, where he was focused on neuroscience. Prior to Lundbeck’s acquisition, he was Director, Corporate Development and M&A at Ovation Pharmaceuticals, a neuroscience-focused company that launched the first product for Huntington’s disease.

Earlier in his career, Micah held financial roles at Eli Lilly and Pfizer. He earned a B.S. in Finance from the Kelley School of Business at Indiana University.